A clinical trial involving more than 3,000 women in the US and southern Africa demonstrates for the first time the promise of a vaginal microbicide gel for preventing HIV infection in women. According to findings, one 0.5 percent dose of a microbicide designed to prevent HIV from attaching to cells in the genital tract, was 30 percent effective.